We are live on ! Find out more
SHI

SV Health Investors Portfolio holdings

AUM $32.3M
1-Year Est. Return 20.15%
This Fund
S&P 500
This Quarter Est. Return
+27.46%
1 Year Est. Return
-20.15%
3 Year Est. Return
+97.4%
5 Year Est. Return
+328.26%
10 Year Est. Return
–
AUM
$32.3M
AUM Growth
-$11.5M
Cap. Flow
-$17.9M
Cap. Flow %
-55.56%
Top 10 Hldgs %
100%
Holding
5
New
–
Increased
–
Reduced
–
Closed
1
Avg Time Held
17 quarters
Top 10 Avg Time Held
17 quarters
Top 20 Avg Time Held
17 quarters

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
AHCO icon
AdaptHealth
AHCO
+$17.9M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
BCYC icon
1
Bicycle Therapeutics
BCYC
$272M
$21.1M 65.36%
907,032
– –
2019 Q2
13 quarters
BVS icon
2
Bioventus
BVS
$892M
$10.4M 32.28%
1,488,596
– –
2021 Q4
3 quarters
XFOR icon
3
X4 Pharmaceuticals
XFOR
$289M
$532K 1.65%
10,383
– –
2017 Q4
19 quarters
ASXC icon
4
DELISTED
Asensus Surgical, Inc.
ASXC
$229K 0.71%
510,142
– –
2014 Q2
33 quarters
AHCO icon
5
AdaptHealth
AHCO
$808M
– –
-994,079
Closed -$17.9M –

Similar funds

SV Health Investors's Q3 2022 Portfolio in Review

As of Q3 2022, SV Health Investors held 5 positions worth $32.3M, down 26% from $43.8M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

SV Health Investors withdrew a net $17.9M in Q3 2022, closing 1 position. Its most notable exit was AdaptHealth, an estimated $17.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • SV Health Investors fully exited AdaptHealth in Q3 2022, selling an estimated $17.9M.
  • SV Health Investors's ten largest holdings make up 100% of its $32.3M portfolio in Q3 2022.
  • SV Health Investors opened 0 new positions and closed 1 in Q3 2022.
  • SV Health Investors's portfolio value fell 26% quarter-over-quarter to $32.3M.

Based on SV Health Investors's 13F filing for Q3 2022, filed 7 Nov 2022.